Related Experiment Video

Updated: Nov 28, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K

Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis

Guocan Yu1, Yanqin Shen2, Xudong Xu1

  • 1Department of thoracic surgery, Zhejiang Chinese Medicine and Western Medicine Integrated Hospital, Hangzhou, Zhejiang, China.

Plos One
|November 30, 2020
PubMed
Abstract

Insights

Anlotinib significantly improves progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and disease control rate (DCR) in advanced non-small-cell lung cancer (NSCLC). Adverse events were tolerable, making anlotinib an effective third-line therapy option.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Advanced non-small-cell lung cancer (NSCLC) presents significant treatment challenges, particularly in refractory cases.
  • Anlotinib is an investigational tyrosine kinase inhibitor with potential anti-cancer activity.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of anlotinib in patients with refractory advanced NSCLC.
  • To determine the impact of anlotinib on progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and disease control rate (DCR).

Main Methods:

  • Systematic search of randomized controlled trials (RCTs) on anlotinib for advanced NSCLC.
  • Meta-analysis of pooled data, calculating hazard ratios (HRs) for PFS and OS, and risk ratios (RRs) for ORR and DCR.
  • Assessment of adverse events (AEs) using odds ratios (ORs).

Main Results:

  • Anlotinib significantly improved PFS (HR: 0.27) and OS (HR: 0.68) in advanced NSCLC patients.
  • Anlotinib demonstrated significantly higher ORR (RR: 11.62) and DCR (RR: 2.30).
  • Grade 3 or higher AEs were more frequent in the anlotinib group (OR: 2.94).

Conclusions:

  • Anlotinib is an effective third- or later-line therapy for refractory advanced NSCLC, offering significant improvements in survival and response rates.
  • The adverse events associated with anlotinib were found to be tolerable.
  • Anlotinib provides clinical benefits for patients with advanced NSCLC who have failed prior treatments.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.2K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
328
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K